Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 334Carcinoma, Renal Cell 112Urinary Bladder Neoplasms 95Breast Neoplasms 55Carcinoma, Transitional Cell 52Colorectal Neoplasms 43Carcinoma, Non-Small-Cell Lung 42Melanoma 41Ovarian Neoplasms 39Kidney Neoplasms 39Neoplasms 38Neoplasm Metastasis 31Lung Neoplasms 28Sarcoma 26Non-Muscle Invasive Bladder Neoplasms 26Uterine Cervical Neoplasms 25Pancreatic Neoplasms 24Endometrial Neoplasms 23Stomach Neoplasms 22Wilms Tumor 19Squamous Cell Carcinoma of Head and Neck 19Carcinoma, Hepatocellular 19Esophageal Neoplasms 18Adenocarcinoma 18Triple Negative Breast Neoplasms 17Head and Neck Neoplasms 17Small Cell Lung Carcinoma 15Thyroid Neoplasms 14Metastatic Castration-resistant Prostate Cancer 14Neuroblastoma 13

Interventions

pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1merphos 1durvalumab 1Vinblastine 1Specimen Handling 1Platinum 1Methotrexate 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Gemcitabine 1Doxorubicin 1Disulfides 1Cisplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Renal Pelvis and Ureter Urothelial Carcinoma × Genitourinary × 30 days × Clear all
NCT04628767 2026-06-03

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
131 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡